Literature DB >> 27858369

Cerebrotendinous Xanthomatosis Presenting with Infantile Spasms and Intellectual Disability.

Austin Larson1,2, James D Weisfeld-Adams3, Tim A Benke4, Penelope E Bonnen5.   

Abstract

Cerebrotendinous xanthomatosis (CTX) is an inborn error of metabolism leading to progressive multisystem disease. Symptoms often begin in the first decade of life with chronic diarrhea, cataracts, developmental delay, intellectual disability, and cerebellar or pyramidal dysfunction. Later manifestations include tendon xanthomas, polyneuropathy, and abnormal neuroimaging. Pathogenic biallelic variants in CYP27A1 leading to compromised function of sterol 27-hydroxylase result in accumulation of detectable toxic intermediates of bile acid synthesis rendering both genetic and biochemical testing effective diagnostic tools. Effective treatment with chenodeoxycholic acid is available, making early diagnosis critical for patient care. Here we report a new patient with CTX and describe the early signs of disease in this patient. Initial symptoms included infantile spasms, which have not previously been reported in CTX. Developmental delay, mild intellectual disability with measured cognitive decline in childhood, was also observed. These clinical signs do not traditionally compel testing for CTX, and we highlight the need to consider this rare but treatable disorder among the differential diagnosis of children with similar clinical presentation. Increased awareness of early signs of CTX is important for improving time to diagnosis for this patient population.

Entities:  

Keywords:  Cataracts; Cerebrotendinous xanthomatosis; Developmental delay; Infantile spasms; Intellectual disability

Year:  2016        PMID: 27858369      PMCID: PMC5585103          DOI: 10.1007/8904_2016_16

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  19 in total

1.  Mutations in the sterol 27-hydroxylase gene (CYP27A) cause hepatitis of infancy as well as cerebrotendinous xanthomatosis.

Authors:  P T Clayton; A Verrips; E Sistermans; A Mann; G Mieli-Vergani; R Wevers
Journal:  J Inherit Metab Dis       Date:  2002-10       Impact factor: 4.982

2.  Clinical and molecular genetic characteristics of patients with cerebrotendinous xanthomatosis.

Authors:  A Verrips; L H Hoefsloot; G C Steenbergen; J P Theelen; R A Wevers; F J Gabreëls; B G van Engelen; L P van den Heuvel
Journal:  Brain       Date:  2000-05       Impact factor: 13.501

3.  A suspicion index for early diagnosis and treatment of cerebrotendinous xanthomatosis.

Authors:  Andrea Mignarri; Gian Nicola Gallus; Maria Teresa Dotti; Antonio Federico
Journal:  J Inherit Metab Dis       Date:  2014-01-18       Impact factor: 4.982

4.  Cerebrotendinous xanthomatosis: the spectrum of imaging findings and the correlation with neuropathologic findings.

Authors:  F Barkhof; A Verrips; P Wesseling; M S van Der Knaap; B G van Engelen; F J Gabreëls; A Keyser; R A Wevers; J Valk
Journal:  Radiology       Date:  2000-12       Impact factor: 11.105

5.  Early-onset epilepsy as the main neurological manifestation of cerebrotendinous xanthomatosis.

Authors:  José Luiz Pedroso; Wladimir B Pinto; Paulo V Souza; Lucas T Santos; Isabela C Abud; Marcela Amaral Avelino; Orlando G Barsottini
Journal:  Epilepsy Behav       Date:  2012-05-30       Impact factor: 2.937

6.  Neurological outcome in cerebrotendinous xanthomatosis treated with chenodeoxycholic acid: early versus late diagnosis.

Authors:  Gilad Yahalom; Rakefet Tsabari; Noa Molshatzki; Lilach Ephraty; Hofit Cohen; Sharon Hassin-Baer
Journal:  Clin Neuropharmacol       Date:  2013 May-Jun       Impact factor: 1.592

7.  Molecular genetics of cerebrotendinous xanthomatosis in Jews of north African origin.

Authors:  A Reshef; V Meiner; V M Berginer; E Leitersdorf
Journal:  J Lipid Res       Date:  1994-03       Impact factor: 5.922

8.  Chronic diarrhea and juvenile cataracts: think cerebrotendinous xanthomatosis and treat.

Authors:  Vladimir M Berginer; Bella Gross; Khayat Morad; Nechama Kfir; Siman Morkos; Salameh Aaref; Tzipora C Falik-Zaccai
Journal:  Pediatrics       Date:  2009-01       Impact factor: 7.124

9.  Mutational analysis of CYP27A1: assessment of 27-hydroxylation of cholesterol and 25-hydroxylation of vitamin D.

Authors:  Ram P Gupta; Kennerly Patrick; Norman H Bell
Journal:  Metabolism       Date:  2007-09       Impact factor: 8.694

10.  On the mechanism of cerebral accumulation of cholestanol in patients with cerebrotendinous xanthomatosis.

Authors:  Ute Panzenboeck; Ulla Andersson; Magnus Hansson; Wolfgang Sattler; Steve Meaney; Ingemar Björkhem
Journal:  J Lipid Res       Date:  2007-02-26       Impact factor: 5.922

View more
  4 in total

Review 1.  Epidemiology, diagnosis, and treatment of cerebrotendinous xanthomatosis (CTX).

Authors:  Gerald Salen; Robert D Steiner
Journal:  J Inherit Metab Dis       Date:  2017-10-04       Impact factor: 4.982

2.  Patients with cerebrotendinous xanthomatosis diagnosed with diverse multisystem involvement.

Authors:  Pelin Teke Kısa; Gonca Kilic Yildirim; Burcu Ozturk Hismi; Sevil Dorum; Ozge Yilmaz Kusbeci; Ali Topak; Figen Baydan; Fatma Nazlı Durmaz Celik; Orhan Gorukmez; Zumrut Arslan Gulten; Arzu Ekici; Serhat Ozkan; Aylin Yaman; Nur Arslan
Journal:  Metab Brain Dis       Date:  2021-03-11       Impact factor: 3.584

Review 3.  West syndrome: a comprehensive review.

Authors:  Piero Pavone; Agata Polizzi; Simona Domenica Marino; Giovanni Corsello; Raffaele Falsaperla; Silvia Marino; Martino Ruggieri
Journal:  Neurol Sci       Date:  2020-08-22       Impact factor: 3.307

4.  Cerebrotendinous Xanthomatosis: Molecular Pathogenesis, Clinical Spectrum, Diagnosis, and Disease-Modifying Treatments.

Authors:  Shingo Koyama; Yoshiki Sekijima; Masatsune Ogura; Mika Hori; Kota Matsuki; Takashi Miida; Mariko Harada-Shiba
Journal:  J Atheroscler Thromb       Date:  2021-05-08       Impact factor: 4.928

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.